Home › Free Stock Grades › GALT
Galectin Therapeutics Inc. (GALT) Stock Grade
GALT · Healthcare
A+
Market Cap
$265.8M
P/E Ratio
—
Revenue Growth (YoY)
0.0%
Net Margin
0.0%
Return on Equity
24.4%
Dividend Yield
0.0%
About Galectin Therapeutics Inc.'s fundamentals
Galectin Therapeutics is a biotech company with a market capitalization of $265.8 million that reported flat revenue with zero year-over-year growth and posted a net loss in its latest annual statement, resulting in a net margin of 0.0%. The company does not pay a dividend, which is typical for development-stage biotech firms. Despite the losses, the company's return on equity stands at 24.4%, indicating efficient deployment of shareholder capital relative to reported earnings.